A landmark mechanistic study from Mass General Brigham, published in Communications Medicine, reveals that the BCG vaccine—traditionally used to prevent tuberculosis—may fundamentally reshape brain immunity in ways that could protect against Alzheimer’s disease. Researchers found that intradermal BCG vaccination triggers sustained changes in brain immune markers that persist for up to 12 months post-vaccination. The vaccine activates a phenomenon called trained immunity, in which innate immune cells undergo metabolic reprogramming that extends beyond initial vaccination to influence microglial function in the brain. These findings provide biological plausibility for epidemiological observations linking BCG exposure to reduced Alzheimer’s incidence, offering a novel mechanistic window into how systemic vaccination might modulate neuroinflammation and potentially slow neurodegeneration. Read the full article on GMJ Newsroom.
Was this article helpful?
